The most commonly reported side effects of technetium tc99m albumin aggregated include cardiac arrest, product label on wrong product, and wrong drug administered, based on 11 FDA adverse event reports from 2013 to 2025.
Percentages show how often each reaction appears relative to total reports for technetium tc99m albumin aggregated.
These are voluntary reports and do not establish that technetium tc99m albumin aggregated caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside technetium tc99m albumin aggregated. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
54.5% of technetium tc99m albumin aggregated adverse event reports involve female patients and 36.4% involve male patients. The largest age group is elderly at 60%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking technetium tc99m albumin aggregated when the adverse event was reported.
Technetium Tc99m Albumin Aggregated is sold under the brand name Pulmotech Maa.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.